Predictmedix | Artificial Intelligence Health Technologies https://predictmedix.com Predictmedix develops cutting edge disruptive tools for impairment testing and healthcare. Fri, 18 Jun 2021 02:00:25 +0000 en-US hourly 1 https://predictmedix.com/wp-content/uploads/2020/10/cropped-PredictMedixGreenWhiteStamp-32x32.png Predictmedix | Artificial Intelligence Health Technologies https://predictmedix.com 32 32 188631865 Predictmedix Inc. Files Registration Statement on Form 20-F with the SEC https://predictmedix.com/pr-06-18-21/?utm_source=rss&utm_medium=rss&utm_campaign=pr-06-18-21 https://predictmedix.com/pr-06-18-21/#respond Fri, 18 Jun 2021 08:15:18 +0000 https://predictmedix.com/?p=232239

 

Toronto, ON / June 18, 2021/ Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”), announced today that it has filed a registration statement on Form 20-F to register its common shares with the United States Securities and Exchange Commission (the “SEC”). Once the registration statement has been declared effective by the SEC, the Company will be a reporting issuer under the United States securities laws.

 

 

About Predictmedix Inc.

 

Predictmedix (CSE: PMED | OTCQB: PMEDF) is an AI (Artificial Intelligence) company developing disruptive technologies for the health and safety of people at work, in public environments, and by supporting healthcare systems with AI powered tools to facilitate better care and outcomes. Our AI powered screening products analyze real-time data from multispectral cameras and other sensors to detect when individuals may exhibiting symptoms of COVID-19 & other infectious diseases and also impairment due to alcohol & cannabis. We are also expanding our technology to screen for mental illnesses such as Alzheimer’s, dementia, and depression. To learn more about our partnerships, where to buy our solutions, and company updates, visit Predictmedix.com.

 

Disclaimer: “The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.”

 

Predictmedix Inc. trades as “PMED” on the Canadian Securities Exchange and “PMEDF” on the OTCQB market in the United States.

 

For more information, visit predictmedix.com

Or follow us on our social media platforms:

Twitter

Instagram

LinkedIn

Information that may be important to investors will be routinely posted on all these sites.

 

Investor Relations:

 

Ehsan Agahi, Investor Relations

Tel: (778) 229-4319

Email: IR@predictmedix.com

 

 

Caution Regarding Forward-Looking Information:

 

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

 

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company’s shares, including price volatility due to events that may or may not be within such party’s control; reliance on management; and the emergency of additional competitors in the industry.

 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

]]> https://predictmedix.com/pr-06-18-21/feed/ 0 232239 Predictmedix Announces Partnership with SBL Testing Technologies for Distribution of Safe Entry Stations https://predictmedix.com/pr-06-11-21/?utm_source=rss&utm_medium=rss&utm_campaign=pr-06-11-21 https://predictmedix.com/pr-06-11-21/#respond Fri, 11 Jun 2021 08:15:36 +0000 https://predictmedix.com/?p=232234

Toronto, ON / June 11, 2021/ Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”), is pleased to announce expansion of their Safe Entry program with the institution of their first distributor, SBL Testing Technologies Inc (SBL) in partnership with JUICEWORKS. 

 

Veterans in risk mitigation, SBL has a long-standing reputation for being at the forefront of innovation in workplace safety, particularly for industrial clients in the energy and resource sectors.  Their territory will include North America and the Caribbean.   With a strong presence in Canada and the US, established multinational clientele, and key partnerships with companies such as Sparta Group (TSX.V:SAY), SBL is aggressively positioned to permeate the industrial vertical with this new offering.

 

Safe Entry Stations are powered by a proprietary artificial intelligence (AI) algorithm developed by Predictmedix Inc. The clinically-based AI was designed by data scientists and clinicians to identify multiple symptoms of infectious disease, displaying the result in the form of a red or green light.

 

The technology can also be configured to screen for impairment by THC and alcohol.  All screening is entirely autonomous and designed to protect the privacy of the end-user.  Completely unique to other solutions on the market, the AI is currently patent pending in North America.

 

“SBL is an ideal partner to bring this technology to market.  They have a unique perspective on the space, having been emersed in it for many years, and appreciate the value of the solution as a long-term risk mitigation tool,” commented Jonathan Auger, President & Founder of JUICEWORKS.  

 

Rich Robillard, Managing Director of SBL, said, “SAFE ENTRY is an incredible screening technology for both short and long-term pandemic response / business continuity strategies. The ability to objectively screen for infectious disease symptoms non-invasively and in seconds presents an entirely new first layer of risk mitigation. Albeit responding to the current COVID-19 pandemic and further waves or variants, or planning for future infectious diseases that could impact business continuity, SAFE ENTRY immediately becomes a critical risk mitigation tool in today’s workplace.”

 

“The market positioning of SBL in workplace health safety and testing technologies provides us with an ideal partner to scale SAFE ENTRY both for infectious disease screening along with impairment screening all over North America and the Caribbean. Furthermore, the executive team at SBL has a clear vision and action plan for SAFE ENTRY which aligns with the long-term vision of Predictmedix,” commented Dr. Rahul Kushwah, COO of Predictmedix.

 

 

About SBL Testing Technologies Inc.

 

SBL integrates innovative safety & testing technologies into complex workplaces, aligning to corporate risk profiles, safety programs and operational processes. SBL works with businesses, government agencies, and organizations in all industrial sectors, leveraging technology to reduce risk and enhance policy effectiveness.

SBL’s team has successfully provided risk management, safety solutions & workplace testing technologies for decades. SBL’s workplace drug & alcohol screening and Pandemic Response / Business Continuity solutions are led by a team who collectively have 80+ years of delivering fully integrated solutions to government agencies & Fortune 500 companies worldwide.

Source: SBL

 

 

About JUICEWORKS

 

Founded in 1995 by Jonathan Auger, JUICEWORKS Exhibits began as a one-man team, servicing the exhibit marketing industry.   Jon quickly earned the respect of clients and industry peers. This ultimately resulted in a substantial client increase and agency partners throughout North America.  Today, with 2 North American locations (Toronto, Las Vegas), JUICEWORKS continues to deliver award-winning projects.  Their exponential growth is evident in being recognized by Growth 500 as one of Canada’s fastest-growing companies 3 years running as well as Lenovo’s small business of the year award for 2019.   JUICEWORKS is acknowledged by clients globally as the go-to supplier for innovative design, quality craftsmanship and production.  Their offerings include commercial space design and production, pop-up shops, custom exhibit/event fabrication, experiential marketing, mobile marketing initiatives, museums and general contracting for events.  To find out more, visit juiceworks.ca or getsafeentry.com.

Source: JUICEWORKS EXHIBITS

 

About Predictmedix Inc.

 

Predictmedix Inc. is an artificial intelligence (“AI”) company developing disruptive tools for impairment testing and healthcare. It is intended that the Company’s cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses artificial intelligence to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice.

 

The Company is also developing AI based screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. has expanded its proprietary AI technology to screen for infectious disease symptoms.

 

Additionally, psychiatric disorders such as depression, dementia and Alzheimer’s disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer’s disease. To find out more visit us at www.predictmedix.com

 

Disclaimer: “The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.”

 

For further information, please contact:

 

Ehsan Agahi, Investor Relations

Tel: 778 229 4319

Email: IR@predictmedix.com

 

Caution Regarding Forward-Looking Information:

 

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

 

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company’s shares, including price volatility due to events that may or may not be within such party’s control; reliance on management; and the emergency of additional competitors in the industry.

 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

 

]]> https://predictmedix.com/pr-06-11-21/feed/ 0 232234 Predictmedix Deploys Safe Entry Stations at the Italian Contemporary Film Festival https://predictmedix.com/pr-06-02-21/?utm_source=rss&utm_medium=rss&utm_campaign=pr-06-02-21 https://predictmedix.com/pr-06-02-21/#respond Thu, 03 Jun 2021 08:15:23 +0000 https://predictmedix.com/?p=232223

Toronto, ON / June 3, 2021/ Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”), is pleased to announce the deployment of Safe Entry Stations at the Lavazza Drive In Film Festival to be held in Ontario from June 27 to July 17.

 

Inaugurated as a grassroots non-profit film festival in 2012, Italian Contemporary Film Festival (ICFF) has grown to become one of the largest Italian film festivals outside of Italy. Launched last year with the desire to reconnect audiences and communities, and support the countries most affected by the pandemic, the Lavazza Drive-In Film Festival was able to safely bring an audience of over 20,000 people to the cities of Toronto, Vaughan and Markham. This year, the festival returns to Toronto’s playground, Ontario Place, with an enhanced multicultural program of three weeks that will take the audience on a journey across 16 different countries.  

 

Safe Entry Stations will be deployed to screen staff at the Lavazza Drive-In Film Festival organized by ICFF and CHIN between June 27 and July 17, 2021.  It will then be used to rapidly screen patrons and staff prior to access to open-air screenings, set to begin mid-July.

 

Safe Entry Stations utilize a proprietary AI algorithm to provide a rapid (approx. 2 seconds), robust, and non-invasive screening, including multi-symptom detection of infectious diseases, such as COVID-19.

 

The deployment marks the third of its kind in the live event space and the Company’s expansion into a new industry vertical. Previous deployments included a series of VIP parties at the Super Bowl in February as well as a recently announced partnership for HockeyFest, a travelling hockey tournament slated to begin July 9 and hosted throughout North America.  

 

“It’s an honour for Safe Entry to collaborate with the ICFF team to create a safer event where Torontonians can come together once again to enjoy the arts.” commented Jonathan Auger, Founder, JUICEWORKS.

 

“With vaccinations on the rise, we are starting to witness what a return to normal could look like. It is important for us to exercise caution, and we’re proud to partner with ICFF to ensure safety is paramount for all participants and visitors,” said Dr. Rahul Kushwah, COO, Predictmedix Inc.   

 

“We’re excited to partner with Juiceworks and Predictmedix’s digital health technology,” says ICFF Co-Founder and Artistic Director Cristiano de Florentiis. “Thanks to their innovative artificial intelligence technology, the festival will give guests peace of mind to finally reconnect in-person with the community after a very long year and the ‘ticket’ to enjoy the breathtaking screenings in open-air venues, completely worry-free.” 

 

About the Lavazza Drive-In Film Festival

 

The ICFF, presented by Lavazza, has teamed up with multicultural media company CHIN Radio/TV once again, in partnership with Ontario Place and the Embassy of Italy in Ottawa, for the second edition of the Lavazza Drive-In Film Festival, from June 27th – July 17th, 2021. This exciting event, presented in collaboration with Rogers Communications and Christie Digital, and funded by the Government of Ontario, offers Canadians an opportunity to reintegrate into society through a safe and socially engaging event. Multiculturalism is at the core of the Lavazza Drive-In Film Festival, which this year will stay true to its International program with a thoughtfully-curated selection of films representing Canada’s cultural mosaic from variety of communities including: Americans, British, Koreans, Latinx, Africans, Chinese, French, Jewish, Japanese, Turkish, Indians, Iranians, Indigenous Peoples and Russians with a special ‘Focus Italia’ series.

 

The festival will open on Canada Multiculturalism day, and will maintain its focus on diversity and expand its reach to engage a wider range of communities and minorities. The film selection will guarantee to shed a light on the intricate texture of Canadian society, bringing forward a vast collection of multicultural stories which will reflect the values of inclusivity and acceptance. The festival will bring the best of contemporary International cinema along with immersive entertainment for guests with red carpet appearances, special guests, celebrity hosts, unique concessions, special events, brand new theatre venues and so much more! 

 

Further information can be found at https://icff.ca/ and  https://icff.ca/icff-film-festival/

 

 

About JUICEWORKS

 

Founded in 1995 by Jonathan Auger, JUICEWORKS Exhibits began as a one-man team, servicing the exhibit marketing industry.   Jon quickly earned the respect of clients and industry peers. This ultimately resulted in a substantial client increase and agency partners throughout North America.  Today, with 2 North American locations (Toronto, Las Vegas), JUICEWORKS continues to deliver award-winning projects.  Their exponential growth is evident in being recognized by Growth 500 as one of Canada’s fastest-growing companies 3 years running as well as Lenovo’s small business of the year award for 2019.   JUICEWORKS is acknowledged by clients globally as the go-to supplier for innovative design, quality craftsmanship and production.  Their offerings include commercial space design and production, pop-up shops, custom exhibit/event fabrication, experiential marketing, mobile marketing initiatives, museums and general contracting for events.  To find out more, visit juiceworks.ca or getsafeentry.com.

Source: JUICEWORKS EXHIBITS

 

About Predictmedix Inc.

 

Predictmedix Inc. is an artificial intelligence (“AI”) company developing disruptive tools for impairment testing and healthcare. It is intended that the Company’s cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses artificial intelligence to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice.

 

The Company is also developing AI based screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. has expanded its proprietary AI technology to screen for infectious disease symptoms.

 

Additionally, psychiatric disorders such as depression, dementia and Alzheimer’s disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer’s disease. To find out more visit us at www.predictmedix.com

 

Disclaimer: “The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.”

 

For further information, please contact:

 

Ehsan Agahi, Investor Relations

Tel: 778 229 4319

Email: IR@predictmedix.com

 

Caution Regarding Forward-Looking Information:

 

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

 

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company’s shares, including price volatility due to events that may or may not be within such party’s control; reliance on management; and the emergency of additional competitors in the industry.

 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

 

]]> https://predictmedix.com/pr-06-02-21/feed/ 0 232223 Predictmedix Announces Technology Deployment at Hockyfest in Partnership with Jones Entertainment Group https://predictmedix.com/pr-05-17-21/?utm_source=rss&utm_medium=rss&utm_campaign=pr-05-17-21 https://predictmedix.com/pr-05-17-21/#respond Mon, 17 May 2021 08:32:19 +0000 https://predictmedix.com/?p=232218

Toronto, ON / May 17, 2021/ Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”) is pleased to announce that Safe Entry Station units will be deployed at the North American tour of Hockeyfest in partnership with Juiceworks Exhibits (JUICEWORKS) and Jones Entertainment Group. The deployments will begin with the first Hockeyfest event, kicking off on June 25, in London, Ontario. Hockeyfest is the world’s largest street and pond hockey festival with tournaments scheduled in 9 cities all over North America. The partnership marks the company’s second deployment in the live-event space, after the widely covered VIP Big Game events during the Superbowl weekend in Tampa Bay, Florida.

Organized by long-time event managers, Jones Entertainment Group, HockeyFest is a highly anticipated event that brings together avid hockey enthusiasts from all over the nation to embrace and partake in the sport. Jones Entertainment Group has raised the bar to ensure that the safety of every participant, vendor, and visitor is of the highest calibre. Working closely with the Chief Medical Officer in the Middlesex-London health unit and Mayor Ed Holder, they have established a robust safety protocol to protect all involved.

The set-up includes a patented HockeyFest rink board system that is half the size of a standard NHL ice rink; staff will sanitize the surface before and after every game.  Additionally, every player, staff and visitor will be screened by a Safe Entry Station before each match to ensure safety standards are enforced for the community.

Safe Entry Stations are powered by a unique proprietary artificial intelligence (AI) algorithm developed by Predictmedix Inc. and offer easy, non-invasive, and robust screening solutions for symptoms of infectious diseases such as COVID-19. The clinically based AI is designed by data scientists and infectious disease specialists and provides individuals with an immediate assessment of the presence of COVID-19 associated symptoms.

“We’re very excited to partner with Predictmedix, Inc. and Juiceworks to deploy their Safe Entry Systems at all of our HockeyFest events in Canada and the United States. The artificial intelligence algorithm they have developed is going to be one of the key components in ensuring the safety of all our players and spectators at each of our events. Travelling with the Safe Entry Systems has given us the opportunity to work with each local Health Unit in a much more diverse way than your standard contract tracing. This will be a game changer in getting back to some sort of normalcy in the sports and entertainment industry,” said Brad Jones, President, Jones Entertainment Group.   

“Hockey is more than just a sport. It is essential to the culture and spirit of Canada, and we are proud that our solutions will revive a tradition that was missed deeply amid a global pandemic. As we expand into the live-event market, we are proud to partner with Jones Entertainment that carries a legacy of over 90 years in the making,” said Dr. Rahul Kushwah, COO, Predictmedix Inc.

“As an avid sports enthusiast, it’s a pleasure to be able to play a part in ensuring people from all over the country are able to enjoy a sense of normalcy and tradition by engaging in a sport we all know and love.  The leadership shown by the whole group at Jones Entertainment is something I truly admire and am proud to be part of,”  said Jonathan Auger, President & Founder of JUICEWORKS.

Safe Entry Stations will be deployed at the following locations and dates for Hockeyfest’s guests and staff:

London, ON – Westmount Shopping Centre

June 25-27, 2021

Summerside, PEI – Credit Union Place

July 1-3, 2021

Edmonton, AB – Northlands Place

July 9-11, 2021

Abbotsford, AB – Abbotsford Centre

July 16-18, 2021

Regina, SK – Conexus Arts Centre

July 23-25, 2021

Ottawa, ON – Canadian Tire Centre

July 30 – Aug 1, 2021

Minneapolis, MN – National Sports Centre

August 13-15, 2021

Winnipeg, MB – Venue TBD

August 25-27, 2021

Information about the event along with the registration information is available at hockeyfestgameon.com

About JUICEWORKS

 

Founded in 1995 by Jonathan Auger, JUICEWORKS Exhibits began as a one-person team, servicing the exhibit marketing industry.   Jon quickly earned the respect of clients and industry peers. This ultimately resulted in a substantial client increase and agency partners throughout North America.  Today, with 2 North American locations (Toronto, Las Vegas), JUICEWORKS continues to deliver award-winning projects.  Their exponential growth is evident in being recognized by Growth 500 as one of Canada’s fastest-growing companies three years running and Lenovo’s small business of the year award for 2019.   JUICEWORKS is acknowledged by clients globally as the go-to supplier for innovative design, quality craftsmanship and production.  Their offerings include commercial space design and production, pop-up shops, custom exhibit/event fabrication, experiential marketing, mobile marketing initiatives, museums, and general contracting for events. 

 

For more information, visit getsafeentry.com or juiceworks.ca

 

About Jones Entertainment Group

Founding their self-named company in 1930, the Jones’ family has branded the Canadian entertainment industry with a legacy of close to 90 years. President, Brad Jones personally manages the touring career of David Feherty, distinguished Golf Commentator. Jones Entertainment Group also produces the largest festival in Southwestern Ontario, Rock the Park, with over 45,000 attendees annually. In 2018, Brad developed the world’s largest travelling street hockey festival, HockeyFest, which travels with full rink board systems across North America. Jones Entertainment is continuously adapting to changes and prides itself on being the leaders of innovation in the sports and entertainment industry.

 

For more information, visit jonesentertainmentgroup.ca

 

About Predictmedix Inc.

 

Predictmedix Inc. is an artificial intelligence (“AI”) company developing disruptive tools for impairment testing and healthcare. It is intended that the Company’s cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses facial and voice recognition to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice.

 

The Company is also developing AI based screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. is expanding its proprietary AI technology to screen for infectious disease symptoms.

 

Additionally, psychiatric disorders such as depression, dementia and Alzheimer’s disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer’s disease.

 

Disclaimer: “The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain Covid-19 (or SARS-2 Coronavirus) at this time.”

Predictmedix trades on the Canadian Securities Exchange (CSE) under the symbol “PMED” and on the OTCQB under the symbol “PMEDF.

For more information, visit predictmedix.com or follow us on Twitter @Predictmedix and Instagram @Predictmedix

Investor Relations:

Ehsan Agahi,

Tel: (778) 229-4319

Email: IR@predictmedix.com

Caution Regarding Forward-Looking Information:

 

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

 

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company’s shares, including price volatility due to events that may or may not be within such party’s control; reliance on management; and the emergency of additional competitors in the industry.

 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

]]> https://predictmedix.com/pr-05-17-21/feed/ 0 232218 Predictmedix announces technology deployment at Long Term Care residence in Edmonton, in partnership with Optima Living https://predictmedix.com/pr-05-06-21/?utm_source=rss&utm_medium=rss&utm_campaign=pr-05-06-21 https://predictmedix.com/pr-05-06-21/#respond Thu, 06 May 2021 08:20:54 +0000 https://predictmedix.com/?p=232211

Toronto, ON / May 6, 2021/ Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”) is pleased to announce deployment of Safe Entry Stations at the Aster Garden Optima Living Community in partnership with Optima Living, Connectus Global, and Juiceworks Exhibits. This marks the market entry into the long-term care and assisted living sectors in North America, which have been hit hard during the current pandemic.

A new, innovative, seniors living community offering independent living and memory care, Aster Gardens started safely welcoming residents on the first day of Spring, March 21. Karen Fitzgerald, Aster Gardens General Manager, said the scanner is one more safeguard that has been put in place to keep residents and others safe from COVID-19 as well as other infectious diseases or viruses.

“At Aster Gardens, we’re extremely pleased to use such ground-breaking technology and lead the way for other seniors’ communities that might consider using it,” said Ali Shivji, Principal of Optima Living. “Optima Living’s focus is always on creating quality, meaningful lives for residents who live in any of our 18 seniors living communities in western Canada.”

“Connectus welcomes the opportunity to be involved in this project with Aster Gardens and working with a sector that has been particularly affected by the COVID-19 pandemic, to make Aster Gardens a safe place for residents to live and for families eventually to be together again. We need to take care of each other now more than ever” said Norine Anderson, COO Connectus Global.

“We’re extremely proud to partner with Optima living and are excited to enter the long-term patient care market. Our AI-powered suite of technology will ensure safer living standards for all members and we are particularly proud to have taken the first step in catering to a safer, more secure community building for patients,” said Dr. Rahul Kushwah, COO, Predictmedix.

This deployment was covered by CTV News which can be watched or read below:

 https://edmonton.ctvnews.ca/video?clipId=2195960

 https://edmonton.ctvnews.ca/thermal-scanner-placed-at-sherwood-park-seniors-home-to-detect-covid-19-1.5415753

 For more details on this release please click on the following video interview:

About Optima Living

Since 2007, Optima Living has established a strong reputation as an owner and operator of seniors’ residential communities located in western Canada. These communities range from Independent to Assisted Living, Long term Care to Memory Care Living, and Residential Mental Health. Optima believes its North Star – Let us welcome you home – is what allows the company’s unique culture to flourish in all its seniors’ residential communities. For further information, visit www.optimaliving.ca

About Aster Gardens

As one of Optima Living’s 10 seniors’ communities in Alberta, Aster Gardens is a 157-suite residence designed for people able to live fully independent lives. In addition to world-class independent living for seniors, Aster Gardens offers the Optima Living Memory Care Program for people with cognitive concerns. The Memory Care Program is rooted in person-centred care and developed in collaboration with the University of Alberta and the University of Manitoba.

About Connectus Global

Connectus is an Alberta based technology company that is leveraging digital technologies for improved safety and productivity in the workplace and is enabling the industry by providing a range of products such as advanced Ultra-Wideband real-time location tracking systems, document digitization, electronic permitting solutions, and access & certification of data, as well as offering business continuity solutions for facilitating safer operations and a streamlined return to work. For any information, contact Connectus by www.connectusglobal.com

 

About JUICEWORKS

 Founded in 1995 by Jonathan Auger, JUICEWORKS Exhibits began as a one-man team, servicing the exhibit marketing industry.   Jon quickly earned the respect of clients and industry peers. This ultimately resulted in a substantial client increase and agency partners throughout North America.  Today, with 2 North American locations (Toronto, Las Vegas), JUICEWORKS continues to deliver award-winning projects.  Their exponential growth is evident in being recognized by Growth 500 as one of Canada’s fastest-growing companies 3 years running as well as Lenovo’s small business of the year award for 2019.   JUICEWORKS is acknowledged by clients globally as the go-to supplier for innovative design, quality craftsmanship and production.  Their offerings include commercial space design and production, pop-up shops, custom exhibit/event fabrication, experiential marketing, mobile marketing initiatives, museums and general contracting for events.  To find out more, visit juiceworks.ca or getsafeentry.com.

Source: JUICEWORKS EXHIBITS

 

 About Predictmedix Inc.

 Predictmedix Inc. is an artificial intelligence (“AI”) company developing disruptive tools for impairment testing and healthcare. It is intended that the Company’s cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses artificial intelligence to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice.

 The Company is also developing AI based screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. has expanded its proprietary AI technology to screen for infectious disease symptoms.

 Additionally, psychiatric disorders such as depression, dementia and Alzheimer’s disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer’s disease. To find out more visit us at www.predictmedix.com

 Disclaimer: “The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.”

 

For further information, please contact:

 

Ehsan Agahi, Investor Relations

Tel: 778 229 4319

Email: IR@predictmedix.com

 

 

Caution Regarding Forward-Looking Information:

 

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

 

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company’s shares, including price volatility due to events that may or may not be within such party’s control; reliance on management; and the emergency of additional competitors in the industry.

 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

]]> https://predictmedix.com/pr-05-06-21/feed/ 0 232211 PREDICTMEDIX ANNOUNCES TECHNOLOGY DEPLOYMENTS AT MAJOR OFFICE TOWERS IN CALGARY AND EDMONTON IN PARTNERSHIP WITH ASPEN PROPERTIES https://predictmedix.com/pr-04-19-21/?utm_source=rss&utm_medium=rss&utm_campaign=pr-04-19-21 https://predictmedix.com/pr-04-19-21/#respond Mon, 19 Apr 2021 08:15:59 +0000 https://predictmedix.com/?p=232194

Toronto, ON / April 19, 2021/ Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”) is pleased to announce deployment of Safe Entry Stations at 4 key office towers in downtown Calgary and Edmonton in partnership with Apsen Properties and Juiceworks Exhibits (Juiceworks). Calgary’s The Edison, Palliser Complex, The Ampersand and Edmonton’s Bell Tower are raising the bar by providing a completely voluntary infectious disease symptom screening option for their tenants. This is a multi-unit, 24 month contract.

 

Safe Entry Stations are powered by artificial intelligence (AI).  Military-grade multispectral cameras use thermal imaging and a proprietary hardware configuration to capture data patterns that are analyzed instantly. They provide an immediate assessment of individuals looking to access shared spaces by screening for multiple symptoms associated with infectious diseases, such as COVID-19.   Moreover, the technology is 100% non-invasive, expediting the screening process even at high volume locations.  

 

This ground-breaking technology is poised to change the way we look at the screening and diagnosis of infectious diseases.  Our autonomous, comprehensive AI algorithms are continuously evolving via machine learning, are deployed instantly on the cloud, and deliver a multi-symptom analysis within seconds.

 

Safe Entry was first brought to Aspen’s Co-founder, Scott Hutcheson’s attention, by long-time friend Michelle Cameron Coulter.   Alberta’s first Olympic Gold Medal Winner and an active member of multiple community organizations, Coulter commented: “As soon as I learned about Safe Entry, I knew I wanted to be involved.  Having the opportunity to play a part in helping re-open our City, Province and Country is an incredible honour.  This ground-breaking technology can meaningfully improve our current quality of life.   I am not surprised that the team at Aspen chose to lead the way in our city. 

 

“We are happy to have Safe Entry Stations in our buildings,” affirms R. Scott Hutcheson, Executive Chair, Aspen Properties. “This form of high volume symptom screening has added an innovative tool to our properties, and offers peace of mind to our tenants and guests in these uncertain times.”

 

“Working with Scott and the whole team at Aspen has been a pleasure.  I have great respect for their commitment to their tenants and desire to pave the way in creating safe spaces,” says Jonathan Auger, President & Founder of JUICEWORKS.

 

Regarding this new partnership, Dr. Rahul Kushwah of PREDICTMEDIX commented:

“We are excited to partner with Aspen Properties as they are a large property management company in Western Canada and are seen as true visionaries in the industry. These deployments pave the way for our further expansion into the commercial real estate sector and being the high-profile locations these are, they offer us great visibility and an unique opportunity to showcase our cutting edge technologies.”

For more details on this release please click on the following video interview:

About JUICEWORKS

Founded in 1995 by Jonathan Auger, JUICEWORKS Exhibits began as a one-man team, servicing the exhibit marketing industry.   Jon quickly earned the respect of clients and industry peers. This ultimately resulted in a substantial client increase and agency partners throughout North America.  Today, with 2 North American locations (Toronto, Las Vegas), JUICEWORKS continues to deliver award-winning projects.  Their exponential growth is evident in being recognized by Growth 500 as one of Canada’s fastest-growing companies 3 years running as well as Lenovo’s small business of the year award for 2019.   JUICEWORKS is acknowledged by clients globally as the go-to supplier for innovative design, quality craftsmanship and production.  Their offerings include commercial space design and production, pop-up shops, custom exhibit/event fabrication, experiential marketing, mobile marketing initiatives, museums and general contracting for events.  To find out more, visit juiceworks.ca or getsafeentry.com.

Source: JUICEWORKS EXHIBITS

 

About ASPEN PROPERTIES

 

Aspen Properties is a privately-held, boutique real estate company that owns and manages commercial office space in downtown Calgary and Edmonton. Aspen focuses on creating welcoming work spaces where people feel connected, get inspired, and know they belong.

Together with their investment partners, Aspen Properties owns and manages approximately 3.8 million square feet of office space in Calgary and Edmonton (plus nearly 3,500 highly sought-after parking spaces in downtown Calgary and Edmonton). Aspen’s current assets comprise 14 buildings—eleven in Calgary, three in Edmonton and development sites in each city.

Aspen buildings typically offer modern and flexible workspaces, full-service meeting and conference facilities, and an unparalleled collection of amenities—gyms, basketball courts, shared bikes, showers & change rooms, and secure bike parking.

 

About Predictmedix Inc.

 

Predictmedix Inc. is an artificial intelligence (“AI”) company developing disruptive tools for impairment testing and healthcare. It is intended that the Company’s cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses artificial intelligence to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice.

 

The Company is also developing AI based screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. has expanded its proprietary AI technology to screen for infectious disease symptoms.

 

Additionally, psychiatric disorders such as depression, dementia and Alzheimer’s disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer’s disease. To find out more visit us at www.predictmedix.com

 

Disclaimer: “The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.”

 

For further information, please contact:

 

Ehsan Agahi, Investor Relations

Tel: 778 229 4319

Email: IR@predictmedix.com

 

Caution Regarding Forward-Looking Information:

 

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

 

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company’s shares, including price volatility due to events that may or may not be within such party’s control; reliance on management; and the emergency of additional competitors in the industry.

 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

 

]]> https://predictmedix.com/pr-04-19-21/feed/ 0 232194 PREDICTMEDIX ANNOUNCES A 2 YEAR REVENUE CONTRACT WITH FLOW ALKALINE SPRING WATER FOR NORTH AMERICAN OPERATIONS https://predictmedix.com/pr-04-14-21/?utm_source=rss&utm_medium=rss&utm_campaign=pr-04-14-21 https://predictmedix.com/pr-04-14-21/#respond Wed, 14 Apr 2021 08:30:15 +0000 https://predictmedix.com/?p=232190

Toronto, ON / April 14, 2021/ Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”) is pleased to announce a 24 month, multi-unit contract to deploy Safe Entry Stations throughout the North American operations of Flow Water Inc. (“Flow Alkaline Spring Water” or “Flow”). The partnership marks the successful completion of our initial pilot, as the technology is now scaled and deployed across all of Flow’s operations both in Canada and the USA. 

 

A pioneer in the health and wellness arena, Flow was one of the first in Eastern Canada to partner with Predictmedix and Juiceworks Exhibits (JUICEWORKS) to implement Safe Entry Stations at their Aurora facilities in August 2020. North America’s first socially responsible artisan alkaline water plant, Flow continues its spirit of innovation by incorporating AI-powered solutions to improve operational efficiencies.

 

Initially deployed as a beta site, Safe Entry quickly became an integral part of Flow’s health and safety protocol.  The autonomous nature of the technology and the robust multi-symptom screening imparted an added sense of security among their workforce.   As part of their ongoing commitment to their valued staff, they have entered into a multi-unit revenue contract for two years and will now be expanding the program to their remaining facilities in Aurora, Ontario and Verona, Virginia.

 

“Implementing Safe Entry at our plants has dramatically decreased our absenteeism and increased employee peace of mind. Keeping our staff safe is top priority, and as such, we were determined to implement the best available solution, which we found in Safe Entry” affirms Nicholas Reichenbach, Founder & Executive Chairman of Flow.

 

Designed by infectious disease experts, along with a global team of data scientists, this patent-pending solution uses artificial intelligence to analyze multiple symptoms associated with COVID-19 and other infectious diseases, providing results in seconds.

 

“Flow is a long-time client, and we are honoured to support them during this challenging time by making things a little easier on their essential workforce.  We value their trust in us and count it a privilege to be out there supporting businesses that are continuing to give back to our communities amid the pandemic” commented Jonathan Auger, President & Founder of JUICEWORKS.

 

“Flow has been one of the earliest adopters of our technology and with them seeing a long-term value in our technology to keep their staff safe is a further testament to the utility of our technology in creating safe workplace environments. We are honoured to support them by deploying our technology throughout their operations in North America” commented Dr. Rahul Kushwah, COO of Predictmedix.

 

About JUICEWORKS

Founded in 1995 by Jonathan Auger, JUICEWORKS Exhibits began as a one-man team, servicing the exhibit marketing industry.   Jon quickly earned the respect of clients and industry peers. This ultimately resulted in a substantial client increase and agency partners throughout North America.  Today, with 2 North American locations (Toronto, Las Vegas), JUICEWORKS continues to deliver award-winning projects.  Their exponential growth is evident in being recognized by Growth 500 as one of Canada’s fastest-growing companies 3 years running as well as Lenovo’s small business of the year award for 2019.   JUICEWORKS is acknowledged by clients globally as the go-to supplier for innovative design, quality craftsmanship and production.  Their offerings include commercial space design and production, pop-up shops, custom exhibit/event fabrication, experiential marketing, mobile marketing initiatives, museums and general contracting for events. 

To find out more, visit juiceworks.ca  or getsafeentry.com

Source: JUICEWORKS EXHIBITS

 

About FLOW®

Flow Water Inc. (“Flow Alkaline Spring Water™” or “Flow®”) is a premium alkaline spring water company with a diversified line of wellness-oriented beverage products sold online and at retailers throughout North America. Flow’s premium alkaline spring water is offered in original unflavored and a range of award-winning organic flavors, in sizes ranging from 330-ml to 1-liter, and in 6, 12, and 24 pack formats. Due to its unique artesian spring sources, Flow products contain naturally occurring electrolytes and essential minerals, and its original and flavored water products have an alkaline pH at the source. As part of its ongoing innovation into wellness beverages, Flow recently introduced new lines of collagen-infused waters with natural flavors, and vitamin-infused waters with certified organic flavors.

 

Founded in 2015 by serial, mission-driven entrepreneur Nicholas Reichenbach, Flow is highly dedicated to sustainability and is a B-Corp Certified company with a purpose to “bring wellness to the world through the positive power of water.” Reichenbach founded Flow believing that its spring water products should be packaged in renewable plant-based Tetra Pak™ cartons using sustainable manufacturing operations.

 

Flow beverage products are available online at flowhydration.com, and are sold at over 25,000 retailers across the United States and Canada, including Whole Foods Market, Loblaws, Sobeys, Metro, Shoppers Drug Mart, Farm Boy, Sprouts Farmers Market, Safeway, Wegmans, Harris Teeter, Walmart, Sam’s Club, Giant Eagle, Bristol Farms, Raley’s, Vitamin Shoppe, and Duane Reade, among others.

Source: Flow

 

About Predictmedix Inc.

Predictmedix Inc. is an artificial intelligence (AI) company developing disruptive tools for impairment testing and healthcare. It is intended that the Company’s cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses AI to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice.

 

The Company is also developing AI based screening for the healthcare industry. The recent advent of the COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. has expanded its proprietary AI technology to screen for infectious disease symptoms.

 

Additionally, psychiatric disorders such as depression, dementia and Alzheimer’s disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer’s disease.

To find out more visit www.predictmedix.com

 

Disclaimer: “The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.”

 

For further information, please contact:

 

Ehsan Agahi, Investor Relations

Tel: 778 229 4319

Email: IR@predictmedix.com

 

 

Caution Regarding Forward-Looking Information:

 

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

 

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company’s shares, including price volatility due to events that may or may not be within such party’s control; reliance on management; and the emergency of additional competitors in the industry.

 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

]]> https://predictmedix.com/pr-04-14-21/feed/ 0 232190 PREDICTMEDIX AND JUICEWORKS FORM STRATEGIC PARTNERSHIP WITH CONNECTUS GLOBAL TO DEPLOY SAFE ENTRY STATIONS NATIONWIDE https://predictmedix.com/pr-04-05-21/?utm_source=rss&utm_medium=rss&utm_campaign=pr-04-05-21 https://predictmedix.com/pr-04-05-21/#respond Mon, 05 Apr 2021 08:15:33 +0000 https://predictmedix.com/?p=232175

Toronto, ON / April 5, 2021/ Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”) is pleased to announce a partnership to deploy Safe Entry Stations in partnership with North American industry leaders JUICEWORKS EXHIBITS (JUICEWORKS) and CONNECTUS Global.

 

SAFE ENTRY STATIONS leverage military-grade multispectral cameras paired with Predictmedix’s proprietary, clinically based artificial intelligence algorithms.  They provide an immediate assessment of individuals looking to access shared spaces by checking for multiple symptoms associated with infectious diseases such as COVID-19.

 

This ground-breaking technology is poised to change the way we look at screening and, eventually, the diagnosis of infectious diseases.   Autonomous, comprehensive analysis provides peace of mind to individuals entering shared spaces, be it for work, entertainment, or necessity.

 

Mike Anderson, CEO of CONNECTUS Global, commented:

 

“Seeing this level of innovation is exciting to drive adoption of digital processes throughout the public and private sectors, what PREDICTMEDIX and JUICEWORKS are doing is revolutionary to introduce a new level of health measurement into the community. Increasing our understanding of what “community health” truly looks like in a way never done before. We are excited about what the future holds and to bring this technology to our partners globally.”

 

The Safe Entry Station is an entirely customizable model which can be retrofitted for permanent, temporary, or mobile applications.

 

“Working with CONNECTUS will allow us to expand our reach by leveraging their extensive network throughout North America.  One of the biggest wins we have experienced as a result of the pandemic is the opportunity to partner with like-minded organizations looking to support communities as we re-ignite our economies and resume our regular routines responsibly and safely.” Says Jonathan Auger, President and Founder of JUICEWORKS

 

Regarding this new alliance, Dr. Rahul Kushwah of PREDICTMEDIX commented:

“We are excited to partner with CONNECTUS Global and offer our AI-powered technologies to their clientele. CONNECTUS Global is offering workplace solutions to clients across North America, and our technology suite complements their technologies which together can make a meaningful difference to the safety of guests, employees in various settings. The roll out of our technology at venues throughout Canada is a major achievement which adds on to our success in Tampa Bay and together this sets us as leaders in the space of providing technology to improve health and safety at live events.”

 

About JUICEWORKS

Founded in 1995 by Jonathan Auger, JUICEWORKS Exhibits began as a one-man team, servicing the exhibit marketing industry.   Jon quickly earned the respect of clients and industry peers. This ultimately resulted in a substantial client increase and agency partners throughout North America.  Today, with 2 North American locations (Toronto, Las Vegas), JUICEWORKS continues to deliver award-winning projects.  Their exponential growth is evident in being recognized by Growth 500 as one of Canada’s fastest-growing companies 3 years running as well as Lenovo’s small business of the year award for 2019.   JUICEWORKS is acknowledged by clients globally as the go-to supplier for innovative design, quality craftsmanship and production.  Their offerings include commercial space design and production, pop-up shops, custom exhibit/event fabrication, experiential marketing, mobile marketing initiatives, museums and general contracting for events.  To find out more, visit juiceworks.ca or getsafeentry.com.

Source: JUICEWORKS EXHIBITS

 

About CONNECTUS GLOBAL

Connectus Global is a leading Alberta-based solutions provider for process automation, worker safety and location monitoring applications across industrial and business sectors. With an integrated suite of digital workforce management and business continuity systems, the company’s internationally deployed solutions work to improve industrial safety, operational efficiency, and crisis recovery planning. Connectus has taken their vast knowledge, experience and technology to expand during the current global situation to provide an extensive turnkey COVID 19 Testing solution for sports, entertainment and businesses to get back to delivering their brand to the public. Contact Connectus Global through their website to see how a custom solution can be utilized for your business. To find out more, visit us at www.connectusglobal.com

Source: Connectus Global

 

 

About Predictmedix Inc.

 

Predictmedix Inc. is an artificial intelligence (“AI”) company developing disruptive tools for impairment testing and healthcare. It is intended that the Company’s cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses artificial intelligence to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice.

 

The Company is also developing AI based screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. has expanded its proprietary AI technology to screen for infectious disease symptoms.

 

Additionally, psychiatric disorders such as depression, dementia and Alzheimer’s disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer’s disease. To find out more visit us at www.predictmedix.com

 

Disclaimer: “The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.”

 

For further information, please contact:

 

Ehsan Agahi, Investor Relations

Tel: 778 229 4319

Email: IR@predictmedix.com

 

 

Caution Regarding Forward-Looking Information:

 

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

 

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company’s shares, including price volatility due to events that may or may not be within such party’s control; reliance on management; and the emergency of additional competitors in the industry.

 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

 

]]> https://predictmedix.com/pr-04-05-21/feed/ 0 232175 PREDICTMEDIX INC. ANNOUNCES ENGAGEMENT OF INVESTMENT BANKING FIRM KINGSWOOD CAPITAL MARKETS https://predictmedix.com/kingswood-capital-pr/?utm_source=rss&utm_medium=rss&utm_campaign=kingswood-capital-pr https://predictmedix.com/kingswood-capital-pr/#respond Mon, 29 Mar 2021 10:00:00 +0000 https://predictmedix.com/?p=232169

Toronto, ON / March 29, 2021/ Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”), a leader in providing AI-powered healthcare solutions is pleased to announce that it has appointed Kingswood Capital Markets (“Kingswood”) in preparation to become a NASDAQ-listed company.

 

The acceptance of the application to list the Company’s common shares on NASDAQ will be subject to a number of regulatory and listing requirements, including without limitation: retaining the required number of market makers for the Company’s common shares; the filing of the applicable registration statement with the U.S. Securities and Exchange Commission to become a reporting company under the U.S. Securities Act; and the review of the Company and acceptance for listing by NASDAQ. There can be no assurance that NASDAQ acceptance will be granted should the Company submit its listing application.

 

Kingswood Capital Markets is a global full-service middle market investment bank. Kingswood helps its clients grow through optimal capital raising structures. Its team of experienced investment professionals has collectively financed over $50 billion in public and private capital markets and provides strategic solutions to clients across a wide spectrum of industries.

Kingswood’s expertise has been engaged to aid in both Predictmedix’s NASDAQ uplist and business growth, as part of the Company’s endeavors to disrupt the current healthcare and technology market in a safe, non-invasive, and economically sustainable way.

“The pandemic has shown us clearly how underprepared we are in dealing with crises. Our mission at Predictmedix has always been to eliminate the systemic cracks in our system to become the first line of defence in workplace health and safety,” said Dr. Rahul Kushwah, COO of Predictmedix.

 

Predictmedix’s path to become a NASDAQ listed company will be a catalyst to the company’s mission of becoming the first line of defence in workplace health and safety.

 

Dr. Kushwah continued, “The importance of the engagement with Kingswood cannot be overstated as we continue to execute our growth strategies towards becoming a leader in AI-Healthcare. We appointed Kingswood for its track record of being a strategic partner for companies in the technology and healthcare verticals. A strategic round of financing and an anticipated NASDAQ listing will be monumental in enabling Predictmedix to execute on its vision and get access to greater capital markets with influential investors.”

 

The listing of the Company’s common shares on the NASDAQ remains subject to the approval of the NASDAQ and the satisfaction of all applicable listing and regulatory requirements. The Company will continue to maintain the listing of its common shares on the Canadian Securities Exchange under the symbol “PMED”. The Company will provide updates on its progress as it moves toward this goal.

 

There is currently no timeline for completion of the review of our capital markets strategy, and there is no assurance that these efforts will be successful or that the review process will result in the listing of the Company’s common shares on NASDAQ.

 

About Predictmedix Inc.

 

Predictmedix Inc. is an artificial intelligence (“AI”) company developing disruptive tools for impairment testing and healthcare. It is intended that the Company’s cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses artificial intelligence to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice.

 

The Company is also developing AI based screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. has expanded its proprietary AI technology to screen for infectious disease symptoms.

 

Additionally, psychiatric disorders such as depression, dementia and Alzheimer’s disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer’s disease. To find out more visit us at www.predictmedix.com

 

Disclaimer: “The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.”

 

For further information, please contact:

 

Ehsan Agahi, Investor Relations

Tel: 778 229 4319

Email: IR@predictmedix.com

 

About Kingswood Capital Markets:

 

Kingswood is a global investment bank founded by experienced investment professionals that have collectively financed over $50 billion in public and private capital markets. Our firm provides a variety of Investment Banking and Advisory services including Equity Financing, Debt Financing and Private Equity Banking. Our team is dedicated to providing objective strategic advice and financing solutions to companies across a full range of industries. For more information, please visit www.kingswoodcm.com.

 

Caution Regarding Forward-Looking Information:

 

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

 

This news release may contain forward-looking statements and information based on current expectations. Forward-looking information in this press release includes statements relating to the Company’s consideration of applying to list its common shares on NASDAQ, the Company’s ability to increase its liquidity and capital markets exposure if the NASDAQ listing application is submitted and is successful, the Company receiving all required approvals in respect of a potential NASDAQ listing application and the commencement of trading of the Company’s Common Shares on the NASDAQ should a listing application be submitted and accepted, the planned registration of the Company’s common shares with the U.S. Securities and Exchange Commission (the “SEC”), the timing of the SEC’s review of the proposed application and any delays, including but not limited to delays related to COVID-19, and the Company’s strategic plans.  These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company’s shares, including price volatility due to events that may or may not be within such party’s control; reliance on management; and the emergency of additional competitors in the industry.

 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

 

]]> https://predictmedix.com/kingswood-capital-pr/feed/ 0 232169 Predictmedix Announces LOI to Acquire SYMP2PASS INC https://predictmedix.com/loi-symp2pass/?utm_source=rss&utm_medium=rss&utm_campaign=loi-symp2pass https://predictmedix.com/loi-symp2pass/#respond Tue, 23 Mar 2021 10:30:45 +0000 https://predictmedix.com/?p=232147

TORONTO, March 23, 2021 (GLOBE NEWSWIRE) — Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”) is pleased to announce it has entered into a letter of intent (the “LOI”), to acquire Symp2Pass Inc. (“Symp2pass”) (the “Acquisition”). The LOI was executed on February 24, 2021 and currently Predictmedix and Symp2pass are working on the definitive agreement.

Symp2Pass is a profitable, revenue generating AI powered IoT product suite of technologies developed by SmartCone Technologies Inc. Symp2Pass had revenues of $2.27 million for the fiscal year ending December 31, 2020 (unaudited) with earnings before taxes of approximately $205,000.

Symp2Pass is one of the first end-to-end advanced touchless health and wellness testing solutions that currently provides advanced COVID-19 symptom screening from multiple independent sensors with geolocation mapping making it unique and more reliable than a single test or measurement. Much like Predictmedix’s Safe Entry Station units, Symp2Pass affords hardware product installation that is coupled with scalable, AI powered software technologies. Beyond the standard questionnaire based screening tools, Symp2Pass measures actual temperature, capable of cough identification, and scent recognition, all critical parts of a more effective screening. Symp2Pass also affords integration capabilities with other IoT products such as RFID bracelets and QR Codes and associated scanners that can assist workplaces in comprehensive employee tracking, tracing, and reporting tying those initial measurements for individuals with multiple automated measurements in various situations during the day. The data collected from the hardware components are immediately uploaded on the cloud and is synthesized with AI-powered technologies within seconds to deliver instant results.

The strategic acquisition will catalyze growth prospects for Predictmedix and will allow the company to offer world class products in line with our mission of becoming the first line of defense in improving workplace health and safety.

Predictmedix’s acquisition of Symp2Pass’s product suite will broaden our target market, complementing our product suite in three strategic ways:

1. Data Collection and Improvement

Data is the lifeblood of an AI-powered solution suite, and with live deployments, Symp2Pass will generate large, high quality datasets that will allow Predictmedix to improve its symptom detection and disease screening technologies. Moreover, the integration of the data sets with our current product suite will allow the simultaneous improvement in the product offering at all Predictmedix and Symp2Pass live installations.

2. Complimentary product installation

The acquisition will allow Symp2Pass product deployments to integrate with Predictmedix’s software suite, which will enhance the functional and operational efficacy of the technology products that are offered by both companies. The complimentary integration of the technology stack will simultaneously improve product efficiency for all our customers.

Symp2Pass’s thermal scanning capabilities allow scans to be completed with an accuracy of ± 0.54° F and can scan up to 30 people at a distance of over nine feet. With Predictmedix’s infectious disease screening algorithms, the company will be able to develop non-invasive screening at scale.

3. Revenue and Market Expansion

In Symp2Pass’s first year of operation, its initial product offering generated revenues of $2.27 million for the fiscal year ended December 31, 2020 (unaudited) with earnings before taxes of approximately $205,000. Symp2Pass current clients include an agency of the Canadian government and a large US utility player.

The ability to screen individuals at entrances and as well as at a distance will allow the firm to expand its current client base to large institutional organizations, universities, and government agencies. The acquisition of future customer contracts based on a recurring revenue model will expedite Predictmedix’s path to profitability and creating value for our stakeholders.

“We at Symp2Pass are very excited to be collaborating with Predictmedix to provide everyone with the first full end-to-end COVID health screening solution. This collaboration will integrate AI (artificial intelligence), biometric analysis, patented hardware and web processes, entrance monitoring, employee tracking and much more. The complete Symp2Pass process will allow people, businesses, governments and countries to get back to work quickly and profitably. Simply, we see it as a future standard for continuing public health and mobility beyond COVID19” stated Symp2Pass CEO Richard Harris.

“There is one word that encapsulates our decision to acquire the Symp2Pass product suite from SmartCone – synergy. From a technology to business development, the acquisition will lead to function improvements in product offerings for both companies. Not only does this mean that all of our existing technologies become better, but also that we’re ramping up revenue generation and building toward sustained, growing profitability with a broader, more robust client base and product offerings,” said Dr. Rahul Kushwah, COO of Predictmedix.

Under the terms of the LOI, the acquisition is valued at approximately $5 million which will be paid in cash and common shares of Predictmedix with the cash component capped at $1 million and the remainder paid out in common shares of Predictmedix with certain milestones, subject to final negotiations. Following completion of the transaction Sypm2pass will be a fully owned entity by Predictmedix.

Completion of the transaction is subject to customary closing conditions, including completion of due diligence, negotiation of definitive agreements and receipt of all necessary approvals. The parties anticipate completing the definitive agreements within the next 30-60 days.

For more details on this release please click on the following video interview:

https://www.globenewswire.com/NewsRoom/AttachmentNg/3c9e4794-f770-4a11-b544-ae4c9cbf7c0e

About Symp2Pass Inc.

Symp2Pass is a collaboration of doctors, researchers, developers, AI specialists and business professionals helping to shape it into the first end-to-end advanced touchless health and wellness testing solution which currently provides advanced Covid-19 screening, analyzing with geo-location mapping.

Symp2Pass starts with a quick private at-home COVID test, using any smart device, the process is:

1)   Adaptable Educational Survey
2)   Patent Pending Scent Test (ScentsiBLE)
3)   Cough identification
4)   Actual Temperature test (completed at Symp2Pass Entrance Kiosk)
5)   Immediate results page
6)   Comprehensive mapping feature:
a.   If having symptoms – map shows local COVID testing centers
b.   If no symptoms – map shows local areas that are safe or suspect of COVID.
7)   Optional Corporate:
a.   Vaccine tracking for employees
b.   Full comprehensive reporting
c.    Employee tracking and tracing.
8)   Artificial Intelligence flexibility will be added to Symp2Pass 2.0 coming in late 2021/early 2022

Symp2Pass is a majority-owned subsidiary of SmartCone Technologies Inc. (“SmartCone”) and its solution was created in SmartCone’s technology incubation program.

About SmartCone Technologies Inc.

SmartCone Technologies Inc. is a unique data sensory company that commercializes new Internet-of-Things (IoT) technologies powering a wide array of sensors, edge computing, sensor fusion and artificial intelligence (AI). Most recently TheSmartCone™ has been seen in “Return to Work” solutions during this COVID-19 pandemic, which includes everything from thermal camera check points to contact tracing and disinfection. Other well know solutions include securing dangerous work sites, controlling bicycle lane traffic, managing vehicle fleets, smart warehouses, crowd control, and more.

SmartCone Technologies Inc. continues to bring new products and novel technologies and solutions to market through its technology incubation program, Innovation Lab, with support and funding from industry and the Canadian Government. Visit us at www.thesmartcone.com 

About Predictmedix Inc.

Predictmedix Inc. is an artificial intelligence (“AI”) company developing disruptive tools for impairment testing and healthcare. It is intended that the Company’s cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses artificial intelligence to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice.

The Company is also developing AI based screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. has expanded its proprietary AI technology to screen for infectious disease symptoms.

Additionally, psychiatric disorders such as depression, dementia and Alzheimer’s disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer’s disease. To find out more visit us at www.predictmedix.com

Disclaimer: “The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.”

For further information, please contact:

Ehsan Agahi, Investor Relations
Tel: 778 229 4319
Email: IR@predictmedix.com

Caution Regarding Forward-Looking Information:

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company’s shares, including price volatility due to events that may or may not be within such party’s control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

]]> https://predictmedix.com/loi-symp2pass/feed/ 0 232147